Oncometabolite D-2-HydroxyGlutarate causes reactive astrogliosis in IDH mutant glioma microenvironment

Oncometabolite D-2-HydroxyGlutarate causes reactive astrogliosis in IDH mutant glioma microenvironment - Astrogliosis IDH Mutant

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00031906

Enrollment

Registered

2023-05-16

Start date

2023-08-01

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

In this comprehensive research endeavor, our primary objective is to recruit a carefully selected cohort of patients who have been accurately classified as having IDH mutant glioma. This entails identifying individuals who have been diagnosed with this specific subtype of glioma characterized by the presence of an isocitrate dehydrogenase (IDH) gene mutation.

Interventions

Group 1: In this project, our aim is to gather cortical and tumor tissue samples from IDH mutant glioma patients for the purpose of establishing an IDH mutant glioma model. By doing so, we seek to del

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: To ensure the robustness and reliability of our study, we will employ stringent inclusion criteria to identify eligible participants who have specific subtype of glioma characterized by the presence of an isocitrate dehydrogenase (IDH) gene mutation.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
To observe the Astrogliosis in IDH mutant Glioma	—

Secondary

Measure	Time frame
Microenvironmental changes in IDH mutant Glioma	—

Countries

Germany

Contacts

Public ContactVidhya Madapusi Ravi

Uniklinikum Freiburg

vidhya.ravi@uniklinik-freiburg.de+4976127050780

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026